Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Sergio Di MatteoRoberto FreiloneGiacomo Matteo BrunoRosario NotaroSabrin MoumeneNicoletta MartoneCristina TeruzziAntonio CiccaroneGiorgio Lorenzo ColomboPublished in: ClinicoEconomics and outcomes research : CEOR (2024)
Pegcetacoplan emerged as the dominant strategy in this analysis, being more effective, less expensive and improves quality of life in the analyzed population affected by PNH.